KURA (Kura Oncology) FCF Yield %: -8.72 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KURA Kura Oncology Inc KURA
28 GF Score
Price $10.91
! 7 Warning Signs
View Full Analysis

What is Kura Oncology FCF Yield %?

Kura Oncology KURA -4.63% 28 FCF Yield % is -8.72 as of Jul. 14, 2026. GuruFocus rates KURA with a GF Score™ of 28/100. The stock has 7 warning signs investors should review. Among 1,409 Biotechnology companies, Kura Oncology ranks better than 51.88% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Kura Oncology's Trailing 12-Month Free Cash Flow is $-84.46 Mil, and Market Cap is $968.08 Mil. Therefore, Kura Oncology's FCF Yield % for today is -8.72%.

The historical rank and industry rank for Kura Oncology's FCF Yield % or its related term are showing as below:

KURA' s FCF Yield % Range Over the Past 10 Years
Min: -11.07   Med: 9.78   Max: 25.32
Current: -8.72


During the past 12 years, the highest FCF Yield % of Kura Oncology was 25.32%. The lowest was -11.07%. And the median was 9.78%.

KURA's FCF Yield % is ranked better than
51.88% of 1409 companies
in the Biotechnology industry
Industry Median: -9.65 vs KURA: -8.72

Kura Oncology's FCF Margin % for the quarter that ended in Mar. 2026 was -470.75%.


Kura Oncology FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Kura Oncology FCF Yield % Related Terms


Kura Oncology FCF Yield % Historical Data

* Premium members only.

The historical data trend for Kura Oncology's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kura Oncology FCF Yield % Chart

Kura Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.34 -13.06 -11.69 19.64 -7.74

Kura Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.18 -24.15 -43.21 50.37 -47.66

KURA vs REPL, AVTX, SANA: FCF Yield % Comparison

For the Biotechnology subindustry, Kura Oncology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kura Oncology FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Kura Oncology's FCF Yield % falls into.


KURA
28GF Score
Kura Oncology Inc KURA
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kura Oncology FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Kura Oncology's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-70.696 / 912.81345
=-7.74%

Kura Oncology's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-85.982 * 4 / 721.64319
=-47.66%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -8.72 mean?
Kura Oncology (KURA) has a FCF Yield % of -8.72 as of Jul. 14, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kura Oncology and its competitors. According to the industry distribution chart, Kura Oncology ranks #678 out of 1409 companies in the Biotechnology industry, placing it in the top 48.1%.
Is Kura Oncology's FCF Yield % too high?
Kura Oncology's current FCF Yield % is -8.72. Based on the distribution chart, Kura Oncology ranks #678 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kura Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's FCF Yield % compare to REPL and AVTX?
According to the Biotechnology industry distribution chart, Kura Oncology ranks #678 out of 1409 companies for FCF Yield %. This puts Kura Oncology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kura Oncology and its competitors. Kura Oncology's current FCF Yield % is -8.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (KURA) has a current FCF Yield % of -8.72. The current FCF Yield % is -8.72. Kura Oncology's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Kura Oncology (KURA), the current FCF Yield % is -8.72 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kura Oncology Business Description

Other Exchanges KUR:Germany
Address 4930 Directors Place, Suite 500, San Diego, CA, USA, 92121
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
28GF Score

Get the complete analysis for KURA

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.91
Price